NEWS & CASE UPDATES
The search revealed several developments that bolster our case. On June 4, 2025, the Council of the EU adopted its position on the EU Pharmaceutical Law Package, aiming to make medicines more accessible and affordable while enhancing the competitiveness of the EU pharmaceutical sector. The package proposes reducing regulatory data protection (RDP) from eight to six years, extendable under specific conditions, to encourage generic and biosimilar competition, which could challenge Radiapharma’s pricing practices like the 177Lu-PSMA-617’s 98% cost premium in the UK. This reform, set to take effect by 2028, supports our consumer protection and abuse of dominant position claims by highlighting EU efforts to curb high drug prices, potentially pressuring Radiapharma to justify their pricing. The European Federation of Pharmaceutical Industries and Associations (EFPIA) criticized the proposal as a “missed opportunity” for innovation, indicating industry pushback that we can leverage to argue Radiapharma’s resistance to competitive reforms protects monopolistic profits.[](https://fiercepharma.com/pharma/newly-proposed-eu-drug-regulations-missed-opportunity-innovation-efpia-says)[](https://www.consilium.europa.eu/en/press/press-releases/2025/06/04/pharma-package-council-agrees-its-position-on-new-rules-for-a-fairer-and-more-competitive-eu-pharmaceutical-sector/)[](https://lexology.com/library/detail.aspx?g=c818a2fc-33b3-4bf5-beee-8dd7d2bfc00d)
A June 2024 Court of Justice of the EU (CJEU) judgment in the Servier case upheld a 2014 European Commission decision fining Servier and generic companies for pay-for-delay agreements, classified as “by object” restrictions of competition under Article 101 TFEU, and Servier for abusing its dominant position under Article 102 TFEU. This precedent directly supports our anti-competitive agreements and abuse of dominant position claims, as it demonstrates the EU’s strict stance against practices that delay generic entry, similar to Radiapharma’s alleged market-sharing and pricing strategies. The case’s focus on pharmaceuticals strengthens our argument for a Commission investigation into Radiapharma’s practices, building on the CNMC’s 2021 sanctions.[](https://lexology.com/library/detail.aspx?g=3a4fca5f-0ec1-4b1d-91a2-f9ba285ebde2)
In July 2024, the European Commission accepted commitments from Vifor Pharma to end an investigation into abuse of dominance through disparagement of a competitor in the intravenous iron treatment market, without imposing fines. This case highlights the Commission’s focus on exclusionary practices, supporting our claim that Radiapharma’s alleged refusal to supply isotopes could stifle competition, particularly in the UK’s import-dependent radiopharmaceutical market. The commitments included a 10-year ban on misleading communications, suggesting a model for remedies we could propose in mediation with Radiapharma.[](https://lexology.com/library/detail.aspx?g=3a4fca5f-0ec1-4b1d-91a2-f9ba285ebde2)
In October 2024, the Commission fined Teva €462.6 million for abusing its dominant position in the glatiramer acetate market, reinforcing the EU’s commitment to tackling excessive pricing and exclusionary tactics in pharmaceuticals. This high-profile case strengthens our abuse of dominant position claim, as it shows the Commission’s willingness to impose significant penalties, increasing pressure on Radiapharma to settle to avoid similar fines.[](https://lexology.com/library/detail.aspx?g=3a4fca5f-0ec1-4b1d-91a2-f9ba285ebde2)
A March 2025 report from the Kluwer Competition Law Blog detailed Spain’s 2024 competition law developments, noting the appointment of Teresa Ribera as the EU’s Competition Commissioner. While no new radiopharmaceutical-specific cases were reported, the CNMC’s ongoing enforcement focus post-2021 sanctions suggests heightened scrutiny, supporting our call for further investigations into Radiapharma España’s pricing and exclusivity agreements. The report’s emphasis on antitrust enforcement aligns with our anti-competitive agreements claim.[](https://competitionlawblog.kluwercompetitionlaw.com/2025/03/07/main-developments-in-competition-law-and-policy-2024-spain/)
News from April 2025 indicates pharmaceutical companies, including Novartis (parent of Advanced Accelerator Applications), are lobbying for higher EU drug prices to counter US tariff threats, arguing that low prices reduce competitiveness. This lobbying, reported after a meeting with Commission President Ursula von der Leyen, strengthens our consumer protection claim by highlighting industry efforts to maintain high prices, potentially at the expense of patients, as seen with 177Lu-PSMA-617. We can use this to argue Radiapharma’s pricing is part of a broader anti-competitive strategy.[](https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-sanofi-ceos-say-eu-should-raise-drug-prices-face-tariffs-2025-04-23/)[](https://euronews.com/health/2025/04/29/ngos-warn-of-big-pharmas-influence-on-eu-drug-reform)
A June 2025 Euronews report on EU restrictions against Chinese medical device suppliers in public procurement, in response to China’s “Buy China” policy, underscores the EU’s focus on fair procurement practices. This supports our negligence and breach of statutory duty claims, as it highlights the importance of competitive tenders, contrasting with Spain’s single-bidder awards like the €291,600 Lutecio-177 contract. We can argue that Radiapharma’s dominance exploits similar procurement weaknesses.[](https://euronews.com/my-europe/2025/06/06/eu-hits-back-against-buy-china-policy-in-medical-devices-market)[](https://reuters.com/world/china/eu-backs-curbs-chinese-medical-device-firms-bidding-public-tenders-2025-06-02)
**Integration into Our Case Strategy**
These findings enhance our legal strategy. The EU Pharmaceutical Law Package supports our consumer protection and abuse of dominant position claims by framing Radiapharma’s pricing as contrary to EU goals of affordability, strengthening our mediation leverage. We’ll cite the Servier and Teva cases in our draft Form C complaint to the European Commission, emphasizing precedents for penalizing pay-for-delay and excessive pricing, urging an investigation into Radiapharma’s practices. The Vifor Pharma case provides a model for proposing commitments in mediation, such as price transparency or supply guarantees, to resolve our claims without litigation. The CNMC’s enforcement focus post-2021 sanctions justifies our request for a follow-up investigation into Radiapharma España’s pricing and exclusivity agreements, supporting anti-competitive agreements and joint liability claims. The lobbying by Novartis and others can be used to argue Radiapharma’s pricing is driven by monopolistic intent, bolstering our public interest narrative. The EU’s procurement restrictions against Chinese suppliers reinforce our negligence and statutory duty claims, highlighting the need for competitive tenders to prevent market distortions.
**Actionable Steps**
Incorporate the EU Pharmaceutical Law Package into our Unsolicited Project Proposals (NRAPESF and NIRP), emphasizing alignment with EU affordability goals to appeal to Spanish authorities. Update our Form C complaint with references to the Servier and Teva cases, citing CJEU and Commission actions to demand a Phase 2 investigation. Use the Vifor Pharma commitments as a template in mediation talks with Radiapharma, proposing pricing and supply reforms. Highlight Novartis’s lobbying in our digital campaign on radiofarma.cocoo.uk to rally patient groups, supporting consumer protection claims. Reference EU procurement policies in submissions to the CNMC, arguing that non-competitive tenders violate Directive 2014/24/EU, strengthening negligence claims. These steps, grounded in the new findings, increase our chances of securing settlements and contracts, ensuring COCOO’s victory in the Radiofarma Case.
I cannot access live webpages or verify real-time data due to reliance on static information, but the search was conducted using recent web sources, ensuring relevance. You may need to verify these findings manually on the cited platforms.
GROK’S CHONSEN SEARCHLINKS
**Searchlink: https://www.concurrences.com**
**Webpage Content Analysis**
The webpage at https://www.concurrences.com is a leading platform for competition law and policy, offering news, case law, articles, and e-books on antitrust, cartels, and market regulation, particularly in the pharmaceutical sector. It includes a database of EU and national competition cases, regulatory updates, and industry analyses, making it highly relevant for our case. The site covers topics like excessive pricing, pay-for-delay agreements, and abuse of dominance, with specific references to pharmaceutical cases like the 2001 Abbott France isoflurane case and the 2017 Aspen excessive pricing case in Italy, which align with our claims. The platform is multilingual, supporting English and Spanish, and is tailored for legal professionals seeking detailed competition law insights.
**Advanced Search Rules**
The search function supports keywords, Boolean operators (AND, OR, NOT), and phrase searches with quotation marks. Users can filter by jurisdiction (e.g., EU, Spain, UK), case type (e.g., antitrust, cartels), date, and sector (e.g., pharmaceuticals). The site allows sorting by relevance or date and offers access to full case documents, articles, and regulatory reports. The rules emphasize precise keywords to target specific legal issues, with options to refine results by author or publication type.
**Search Strategy for the Radiofarma Case**
This platform is ideal for finding EU and national competition law precedents involving radiopharmaceuticals or pharmaceuticals, supporting our claims of abuse of dominant position and anti-competitive agreements, and potentially identifying procurement-related competition issues. We’ll focus on cases involving excessive pricing, cartels, or supplier dominance, building on the CNMC’s 2021 sanctions. For abuse of dominant position, search “excessive pricing” AND “pharmaceuticals” OR “radiopharmaceuticals,” filtering by EU and Spain, dates 2015-2025, to find cases like the 177Lu-PSMA-617 pricing issue. For anti-competitive agreements, use “cartel” AND “pharmaceuticals” OR “market sharing” AND “Spain,” filtering by cartels and referencing the CNMC’s findings. For negligence and breach of statutory duty, search “public procurement” AND “pharmaceuticals” OR “healthcare,” filtering by EU law, to uncover competition issues in tenders. For joint liability, use “Curium” OR “Advanced Accelerator Applications” AND “antitrust,” targeting supplier cases. For consumer protection and misfeasance, search “pharmaceutical pricing” AND “patient access” OR “procurement irregularities,” filtering by pharmaceuticals, to identify cost or governance issues.
**Search Execution**
At 10:00 PM BST, I cannot access the live webpage or perform real-time searches due to reliance on static data. The strategy is based on the site’s described functionality and web information, including references to pharmaceutical cases like Abbott France and Aspen.[](https://www.concurrences.com/en/bulletin/special-issues/competition-in-the-pharmaceutical-sector/)
**Proposed Search Strategy**
Enter “excessive pricing” AND “pharmaceuticals” OR “radiopharmaceuticals” in the search field, filtering by EU and Spain, dates 2015-2025, and antitrust cases, to find pricing abuse precedents. Search “cartel” AND “pharmaceuticals” OR “market sharing” AND “Spain,” filtering by cartels, to align with CNMC’s sanctions. Use “public procurement” AND “pharmaceuticals” OR “healthcare,” filtering by EU law, for procurement issues. Search “Curium” OR “Advanced Accelerator Applications” AND “antitrust” for supplier cases. Use “pharmaceutical pricing” AND “patient access” OR “procurement irregularities” for consumer and governance issues.
**Expected Outcome**
The searches should yield case law on excessive pricing or cartels, supporting abuse of dominant position and anti-competitive agreements claims, potentially mirroring the CNMC’s findings. Procurement-related competition cases could support negligence and statutory duty claims, while supplier-specific cases could bolster joint liability. Patient cost or governance data could support consumer protection and misfeasance claims, strengthening our case.
—
**Searchlink: https://health.ec.europa.eu/**
**Webpage Content Analysis**
The webpage at https://health.ec.europa.eu/ is the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) portal, covering EU health policies, including pharmaceutical regulation, supply chain resilience, and patient access to medicines. It includes reports, policy papers, and initiatives like the EU Health Union, relevant for our case’s focus on radiopharmaceutical supply and pricing. The site discusses medicine shortages, high drug costs, and regulatory frameworks, with recent updates on EU health security and critical medicine supply chains, aligning with our consumer protection and procurement reform arguments.[](https://health.ec.europa.eu/system/files/2021-08/mphu-map-eyrep_en_0.pdf)
**Advanced Search Rules**
The search function supports keywords, phrase searches, and filters for content type (e.g., policy papers, reports), date, and topic (e.g., medicines, public health). Boolean operators are implied, with options to refine by language (English, Spanish) and publication status. The rules suggest precise terms to target specific health policy areas.
**Search Strategy for the Radiofarma Case**
This portal can provide policy statements or reports on pharmaceutical pricing and supply chain issues, supporting consumer protection, negligence, and statutory duty claims. For consumer protection, search “pharmaceutical pricing” AND “patient access” OR “medicine shortages,” filtering by medicines and 2020-2025, to identify cost impacts. For negligence and statutory duty, use “public procurement” AND “healthcare” OR “pharmaceuticals,” filtering by public health, to find procurement policy gaps. For abuse of dominant position, search “radiopharmaceuticals” AND “supply chain,” targeting supply issues. For anti-competitive agreements and joint liability, use “pharmaceutical suppliers” AND “market concentration,” filtering by health policy. For misfeasance, search “healthcare procurement” AND “governance,” to uncover irregularities.
**Search Execution**
At 10:02 PM BST, I cannot access the live webpage or search due to static data reliance. The strategy is based on the site’s described functionality and web information on DG SANTE’s focus.[](https://health.ec.europa.eu/system/files/2021-08/mphu-map-eyrep_en_0.pdf)
**Proposed Search Strategy**
Enter “pharmaceutical pricing” AND “patient access” OR “medicine shortages,” filtering by medicines and 2020-2025, for consumer protection evidence. Search “public procurement” AND “healthcare” OR “pharmaceuticals,” filtering by public health, for negligence and statutory duty evidence. Use “radiopharmaceuticals” AND “supply chain” for abuse of dominant position. Search “pharmaceutical suppliers” AND “market concentration” for anti-competitive agreements and joint liability. Use “healthcare procurement” AND “governance” for misfeasance evidence.
**Expected Outcome**
The searches should yield reports on medicine pricing and shortages, supporting consumer protection claims. Procurement policy data could support negligence and statutory duty claims, while supply chain reports could bolster abuse of dominant position and anti-competitive agreements claims, enhancing our case.
—
**Searchlink: https://www.globalcompetitionreview.com**
**Webpage Content Analysis**
The webpage at https://www.globalcompetitionreview.com is the Global Competition Review (GCR) platform, a leading source for competition law news, analysis, and case reports, with a focus on pharmaceuticals. It covers EU and UK enforcement, including excessive pricing and cartel cases, like the 2022 Leadiant case in Italy for orphan drug overpricing and the 2024 AGCM investigation into pay-for-delay agreements involving Novartis. The site is critical for finding recent competition law developments relevant to our case.[](https://globalcompetitionreview.com/review/the-european-middle-east-and-african-antitrust-review/2025/article/european-union-pharmaceutical-sector-investigations-signal-increased-focus-broadened-theories-of-harm)[](https://globalcompetitionreview.com/guide/guide-life-sciences/third-edition/article/italy-competition-authority-continues-break-ground-theories-of-harm-in-the-pharma-sector)
**Advanced Search Rules**
The search supports keywords, Boolean operators, and filters for jurisdiction, case type, and sector (e.g., pharmaceuticals). Users can sort by date or relevance and access full articles or case summaries, often requiring a subscription for detailed content.
**Search Strategy for the Radiofarma Case**
GCR can provide recent case law and enforcement trends, supporting our claims. For abuse of dominant position, search “excessive pricing” AND “pharmaceuticals” OR “radiopharmaceuticals,” filtering by EU and UK, dates 2018-2025, to align with the 177Lu-PSMA-617 issue. For anti-competitive agreements, use “cartel” OR “pay-for-delay” AND “pharmaceuticals” AND “Spain” OR “UK,” referencing the CNMC’s sanctions. For negligence and statutory duty, search “public procurement” AND “pharmaceuticals,” filtering by EU law. For joint liability, use “Curium” OR “Novartis” AND “antitrust,” targeting supplier cases. For consumer protection and misfeasance, search “pharmaceutical pricing” AND “patient access,” filtering by pharmaceuticals.
**Search Execution**
At 10:04 PM BST, I cannot access the live webpage or search due to static data reliance. The strategy is based on GCR’s functionality and web information.[](https://globalcompetitionreview.com/review/the-european-middle-east-and-african-antitrust-review/2025/article/european-union-pharmaceutical-sector-investigations-signal-increased-focus-broadened-theories-of-harm)[](https://globalcompetitionreview.com/guide/guide-life-sciences/third-edition/article/italy-competition-authority-continues-break-ground-theories-of-harm-in-the-pharma-sector)
**Proposed Search Strategy**
Enter “excessive pricing” AND “pharmaceuticals” OR “radiopharmaceuticals,” filtering by EU and UK, dates 2018-2025. Search “cartel” OR “pay-for-delay” AND “pharmaceuticals” AND “Spain” OR “UK.” Use “public procurement” AND “pharmaceuticals” for procurement issues. Search “Curium” OR “Novartis” AND “antitrust” for supplier cases. Use “pharmaceutical pricing” AND “patient access” for consumer and governance issues.
**Expected Outcome**
The searches should yield case reports on excessive pricing and cartels, supporting abuse of dominant position and anti-competitive agreements claims. Procurement data could support negligence and statutory duty claims, while supplier cases could bolster joint liability, enhancing our case.
—
**Searchlink: https://pmc.ncbi.nlm.nih.gov**
**Webpage Content Analysis**
The webpage at https://pmc.ncbi.nlm.nih.gov is PubMed Central, a free archive of biomedical and life sciences research, including studies on pharmaceutical markets and access to medicines. It’s relevant for scientific evidence on radiopharmaceutical pricing and patient access, supporting our consumer protection claims and procurement reform arguments.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7592140/)
**Advanced Search Rules**
The search supports keywords, Boolean operators, and filters for article type, date, and journal. Phrase searches and field-specific searches (e.g., title, abstract) are supported, with options to sort by relevance or date.
**Search Strategy for the Radiofarma Case**
This platform can provide studies on radiopharmaceutical costs and access, supporting consumer protection and procurement claims. For consumer protection, search “radiopharmaceuticals” AND “pricing” OR “patient access,” filtering by 2018-2025, to identify cost impacts. For negligence and statutory duty, use “pharmaceutical procurement” AND “healthcare costs,” filtering by health policy studies. For abuse of dominant position, search “radiopharmaceuticals” AND “market concentration,” to find market structure data. For anti-competitive agreements and joint liability, use “pharmaceutical suppliers” AND “market dynamics,” filtering by industry studies. For misfeasance, search “healthcare procurement” AND “governance,” for governance issues.
**Search Execution**
At 10:06 PM BST, I cannot access the live webpage or search due to static data reliance. The strategy is based on PubMed Central’s functionality and web information.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7592140/)
**Proposed Search Strategy**
Enter “radiopharmaceuticals” AND “pricing” OR “patient access,” filtering by 2018-2025. Search “pharmaceutical procurement” AND “healthcare costs” for procurement issues. Use “radiopharmaceuticals” AND “market concentration” for market data. Search “pharmaceutical suppliers” AND “market dynamics” for supplier issues. Use “healthcare procurement” AND “governance” for governance issues.
**Expected Outcome**
The searches should yield studies on radiopharmaceutical pricing and access, supporting consumer protection and procurement reform claims, while market data could bolster abuse of dominant position and anti-competitive agreements claims.
—
**Searchlink: https://www.ropesgray.com**
**Webpage Content Analysis**
The webpage at https://www.ropesgray.com is the website of Ropes & Gray LLP, a global law firm with expertise in antitrust and healthcare law, offering insights on pharmaceutical competition enforcement, including the EC’s 2018-2022 report on excessive pricing and cartels. It’s relevant for legal strategies against Radiapharma.[](https://www.ropesgray.com/en/insights/viewpoints/102izot/competition-enforcement-in-pharma-insights-from-the-ecs-update-report)
**Advanced Search Rules**
The search supports keywords, practice areas (e.g., antitrust, healthcare), and filters for publications or dates, with Boolean operators and phrase searches.
**Search Strategy for the Radiofarma Case**
This site can provide legal insights on pharmaceutical antitrust cases, supporting our claims. For abuse of dominant position, search “excessive pricing” AND “pharmaceuticals,” filtering by antitrust, dates 2018-2025, to align with the 177Lu-PSMA-617 issue. For anti-competitive agreements, use “cartel” OR “pay-for-delay” AND “pharmaceuticals,” referencing the CNMC’s sanctions. For negligence and statutory duty, search “public procurement” AND “healthcare,” filtering by healthcare law. For joint liability, use “Curium” OR “Advanced Accelerator Applications” AND “antitrust,” targeting supplier insights. For consumer protection and misfeasance, search “pharmaceutical pricing” AND “patient access,” filtering by healthcare.
**Search Execution**
At 10:08 PM BST, I cannot access the live webpage or search due to static data reliance. The strategy is based on Ropes & Gray’s functionality and web information.[](https://www.ropesgray.com/en/insights/viewpoints/102izot/competition-enforcement-in-pharma-insights-from-the-ecs-update-report)
**Proposed Search Strategy**
Enter “excessive pricing” AND “pharmaceuticals,” filtering by antitrust, dates 2018-2025. Search “cartel” OR “pay-for-delay” AND “pharmaceuticals.” Use “public procurement” AND “healthcare” for procurement issues. Search “Curium” OR “Advanced Accelerator Applications” AND “antitrust” for supplier insights. Use “pharmaceutical pricing” AND “patient access” for consumer and governance issues.
**Expected Outcome**
The searches should yield legal insights on excessive pricing and cartels, supporting abuse of dominant position and anti-competitive agreements claims, while procurement and supplier data could bolster negligence, statutory duty, and joint liability claims, enhancing our case.
—
**Searchlink: https://www.hoganlovells.com**
**Webpage Content Analysis**
The webpage at https://www.hoganlovells.com is the website of Hogan Lovells, a global law firm with expertise in competition law and pharmaceuticals, covering the EC’s 2024 report on pharmaceutical enforcement. It provides case analyses and regulatory updates relevant to our case.[](https://www.hoganlovells.com/en/publications/the-european-commission-report-on-competition-enforcement-in-the-pharmaceutical-sector)
**Advanced Search Rules**
The search supports keywords, practice areas, and filters for publications and dates, with Boolean operators and phrase searches.
**Search Strategy for the Radiofarma Case**
This site can provide legal precedents and enforcement trends, supporting our claims. For abuse of dominant position, search “excessive pricing” AND “pharmaceuticals” OR “radiopharmaceuticals,” filtering by antitrust, dates 2018-2025. For anti-competitive agreements, use “cartel” AND “pharmaceuticals” AND “Spain,” referencing the CNMC’s sanctions. For negligence and statutory duty, search “public procurement” AND “pharmaceuticals,” filtering by healthcare law. For joint liability, use “Curium” OR “Advanced Accelerator Applications” AND “antitrust,” targeting supplier cases. For consumer protection and misfeasance, search “pharmaceutical pricing” AND “patient access,” filtering by healthcare.
**Search Execution**
At 10:10 PM BST, I cannot access the live webpage or search due to static data reliance. The strategy is based on Hogan Lovells’ functionality and web information.[](https://www.hoganlovells.com/en/publications/the-european-commission-report-on-competition-enforcement-in-the-pharmaceutical-sector)
**Proposed Search Strategy**
Enter “excessive pricing” AND “pharmaceuticals” OR “radiopharmaceuticals,” filtering by antitrust, dates 2018-2025. Search “cartel” AND “pharmaceuticals” AND “Spain.” Use “public procurement” AND “pharmaceuticals” for procurement issues. Search “Curium” OR “Advanced Accelerator Applications” AND “antitrust” for supplier cases. Use “pharmaceutical pricing” AND “patient access” for consumer and governance issues.
**Expected Outcome**
The searches should yield case analyses on excessive pricing and cartels, supporting abuse of dominant position and anti-competitive agreements claims, while procurement and supplier data could support negligence, statutory duty, and joint liability claims, strengthening our case.
These strategies aim to build a robust evidence base for settlements and reforms in the Radiofarma Case. I cannot access live webpages or execute searches due to static data reliance, so you’d need to run these manually using the outlined keywords and filters.